ArticleCommunications medicine2023
Precision gestational diabetes treatment: a systematic review and meta-analyses.
Article in Communications medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Association of CDKAL1 gene polymorphisms variations with gestational diabetes mellitus risk in women: A case-control study and meta-analysis.BMC endocrine disorders · 2025Pooled it
- Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta-analysis.Diabetic medicine : a journal of the British Diabetic Association · 2025Pooled it
- Patient Engagement Strategies for Women with Gestational Diabetes Mellitus in Low-Resource Community Health Settings: A Narrative Review and Clinical Principles.Healthcare (Basel, Switzerland) · 2026Review
- Metformin and Hypertensive Disorders of Pregnancy: A Phenotype-Based Focused Narrative Review.Journal of clinical medicine · 2026Review
- Advancing Personalized Medicine in Gestational Diabetes Mellitus Management Through Gut Microbiota Insights.International journal of molecular sciences · 2026Review
- The use of machine learning to predict pharmacological therapy in gestational diabetes: A scoping review.Diabetic medicine : a journal of the British Diabetic Association · 2026Review
- Precision Medicine and Shared Decision-Making to Advance Gestational Diabetes Management: Genetic, Metabolic, and Gut Microbiota Factors.Patient preference and adherence · 2026Review
- Gut microbiota contributes to gestational diabetes mellitus by interfering with bile acid metabolism and resistin.Frontiers in cellular and infection microbiology · 2026Article
- Comprehensive Review of Gestational Diabetes: Pathophysiology, Pharmacological Management and the Role of Pharmaceutical Care.Current drug safety · 2026Review
- Early Gestational Diabetes Mellitus: A Need for Better Understanding and Wise Navigation.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- GDM as a unique pathophysiological entity or a transitional pregnancy-induced glucose metabolism abnormality identifying primary diabetes types?Frontiers in physiology · 2026Review
- Incretin receptor agonism during pregnancy: implications for mother and baby.Clinical science (London, England : 1979) · 2025Review
- Gestational diabetes mellitus subtypes: from one-size-fits-all to precision medicine.Hormones (Athens, Greece) · 2025Review
- Individual Prediction of Insulin Therapy in Gestational Diabetes: Development of a Risk Calculator Based on Real-World Data from the GestDiab Registry.Geburtshilfe und Frauenheilkunde · 2025Article
- Chrononutrition in Gestational Diabetes: Toward Precision Timing in Maternal Care.Journal of personalized medicine · 2025Review
- Hemoglobin A1C in the first trimester of pregnancy as a predictor of gestational diabetes mellitus: A retrospective study in Saudi Arabia.Journal of family medicine and primary care · 2025Article
- From Molecular Insights to Clinical Management of Gestational Diabetes Mellitus-A Narrative Review.International journal of molecular sciences · 2025Review
- Developing a Risk Stratification Tool to Predict Patients with Gestational Diabetes Mellitus at Risk of Insulin Treatment: A Cohort Study.Journal of personalized medicine · 2025Article
- A critique of measurement of defective insulin secretion and insulin sensitivity as a precision approach to gestational diabetes.Diabetologia · 2025Observational
- Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 20 institutions in 26 countries.
Funding
Abstract
backgroundGestational Diabetes Mellitus (GDM) affects approximately 1 in 7 pregnancies globally. It is associated with short- and long-term risks for both mother and baby. Therefore, optimizing treatment to effectively treat the condition has wide-ranging beneficial effects. However, despite the known heterogeneity in GDM, treatment guidelines and approaches are generally standardized. We hypothesized that a precision medicine approach could be a tool for risk-stratification of women to streamline successful GDM management. With the relatively short timeframe available to treat GDM, commencing effective therapy earlier, with more rapid normalization of hyperglycaemia, could have benefits for both mother and fetus.
methodsWe conducted two systematic reviews, to identify precision markers that may predict effective lifestyle and pharmacological interventions.
resultsThere was a paucity of studies examining precision lifestyle-based interventions for GDM highlighting the pressing need for further research in this area. We found a number of precision markers identified from routine clinical measures that may enable earlier identification of those requiring escalation of pharmacological therapy (to metformin, sulphonylureas or insulin). This included previous history of GDM, Body Mass Index and blood glucose concentrations at diagnosis.
conclusionsClinical measurements at diagnosis could potentially be used as precision markers in the treatment of GDM. Whether there are other sensitive markers that could be identified using more complex individual-level data, such as omics, and if these can feasibly be implemented in clinical practice remains unknown. These will be important to consider in future studies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.